PL3160498T3 - Cząsteczki na bazie IL-15 i sposoby ich zastosowania - Google Patents

Cząsteczki na bazie IL-15 i sposoby ich zastosowania

Info

Publication number
PL3160498T3
PL3160498T3 PL15815782T PL15815782T PL3160498T3 PL 3160498 T3 PL3160498 T3 PL 3160498T3 PL 15815782 T PL15815782 T PL 15815782T PL 15815782 T PL15815782 T PL 15815782T PL 3160498 T3 PL3160498 T3 PL 3160498T3
Authority
PL
Poland
Prior art keywords
methods
application
molecules based
molecules
Prior art date
Application number
PL15815782T
Other languages
English (en)
Inventor
Bai LIU
Peter Rhode
Wenxin Xu
Hing C. Wong
Original Assignee
Altor Bioscience Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience Corporation filed Critical Altor Bioscience Corporation
Publication of PL3160498T3 publication Critical patent/PL3160498T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL15815782T 2014-06-30 2015-06-30 Cząsteczki na bazie IL-15 i sposoby ich zastosowania PL3160498T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018899P 2014-06-30 2014-06-30
PCT/US2015/038587 WO2016004060A2 (en) 2014-06-30 2015-06-30 Il-15-based molecules and methods of use thereof
EP15815782.6A EP3160498B1 (en) 2014-06-30 2015-06-30 Il-15-based molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3160498T3 true PL3160498T3 (pl) 2022-02-21

Family

ID=54929364

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15815782T PL3160498T3 (pl) 2014-06-30 2015-06-30 Cząsteczki na bazie IL-15 i sposoby ich zastosowania

Country Status (11)

Country Link
US (18) US9925247B2 (pl)
EP (3) EP3912637A1 (pl)
JP (5) JP6842926B2 (pl)
KR (4) KR102503476B1 (pl)
CN (3) CN113384686B (pl)
AU (4) AU2015284248B2 (pl)
CA (2) CA3151221C (pl)
ES (1) ES2899890T3 (pl)
MX (1) MX387159B (pl)
PL (1) PL3160498T3 (pl)
WO (1) WO2016004060A2 (pl)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2160401T3 (da) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
WO2018112219A1 (en) * 2016-12-14 2018-06-21 Nant Holdings Ip, Llc Superkine
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
CA3151221C (en) 2014-06-30 2026-01-13 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
CA2973109A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for ebola virus vaccination
KR102193635B1 (ko) 2015-01-09 2020-12-21 이투빅스 코포레이션 복합 면역요법을 위한 방법 및 조성물
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
MX389194B (es) 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
US11001631B2 (en) * 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
WO2017177175A1 (en) * 2016-04-07 2017-10-12 The George Washington University Methods and compositions targeting retroviral latency
AU2017271593B2 (en) 2016-05-27 2021-04-22 Altor Bioscience Corporation Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
CN109890408A (zh) 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法
WO2018005973A1 (en) * 2016-06-30 2018-01-04 Nant Holdings Ip, Llc Nant cancer vaccine
CN110214147A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15Rα异源二聚体FC-融合蛋白
CN118562016A (zh) * 2016-10-21 2024-08-30 艾尔特生物科技公司 基于多聚体il-15的分子
WO2018081830A1 (en) * 2016-10-31 2018-05-03 Oregon Health & Science University Combinations of agents to treat hematological malignancies
RU2019122408A (ru) * 2017-01-20 2021-02-20 Новартис Аг Средство комбинированной терапии для лечения рака
US20200237874A1 (en) * 2017-01-20 2020-07-30 Novartis Ag Combination therapy for the treatment of cancer
US10440535B2 (en) 2017-01-25 2019-10-08 The George Washington University System and method for asset-agnostic wireless monitoring and predictive maintenance of deployed assets
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN117986384A (zh) 2017-03-06 2024-05-07 艾尔特生物科技公司 与il-12和il-18的基于il-15的融合物
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
AU2018265534A1 (en) * 2017-05-11 2019-10-31 Nantkwest, Inc. Anti-EGFR/high affinity NK-cells compositions and methods for chordoma treatment
CN110831620A (zh) * 2017-05-26 2020-02-21 埃特彼塞斯公司 包含il-15超激动剂的联合免疫疗法
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
CN108070556A (zh) * 2017-07-26 2018-05-25 深圳市北科生物科技有限公司 用于免疫细胞培养的方法和组合物
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
AU2018360045B2 (en) * 2017-11-03 2025-04-17 Precision Biologics, Inc. Monoclonal antibody NEO-201 for the treatment of human carcinomas
US20190241665A1 (en) * 2018-01-25 2019-08-08 Wisconsin Alumni Research Foundation Methods of inhibiting metastasis in cancer
WO2019147925A1 (en) 2018-01-26 2019-08-01 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
JP2021514625A (ja) * 2018-03-01 2021-06-17 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物
TW202003011A (zh) 2018-03-26 2020-01-16 美商艾爾特生物科技責任有限公司 抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子
CA3097625A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
KR20210003813A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
TWI905535B (zh) 2018-04-23 2025-11-21 美商南特細胞公司 新抗原表位疫苗及免疫刺激組合物及方法
US11564980B2 (en) 2018-04-23 2023-01-31 Nantcell, Inc. Tumor treatment method with an individualized peptide vaccine
JP6630026B1 (ja) * 2018-04-27 2020-01-15 隆代 大田 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー
US11134120B2 (en) 2018-05-18 2021-09-28 Inveniam Capital Partners, Inc. Load balancing in blockchain environments
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US11701408B2 (en) * 2018-10-11 2023-07-18 Nantcell, Inc. Treatment of immunosuppressed subjects
AU2019359475A1 (en) 2018-10-12 2021-05-20 Xencor, Inc. PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
WO2020097556A1 (en) * 2018-11-09 2020-05-14 Nektar Therapeutics Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent
EP3896089A4 (en) * 2018-12-13 2022-09-07 Jiangsu Hengrui Medicine Co., Ltd. USE OF IL-15 PROTEIN COMPLEXES IN CONJUNCTION WITH PD-L1 ANTIBODIES FOR THE TREATMENT OF TUMOR DISEASES
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
US12497435B2 (en) * 2019-01-11 2025-12-16 Memorial Sloan Kettering Cancer Center Multimerization of IL-15/IL-15R-alpha-fc complexes to enhance immunotherapy
US12502404B1 (en) 2019-03-15 2025-12-23 Nantbio, Inc. Conditional modulation of therapy using recombinant cells
US20220218789A1 (en) 2019-05-10 2022-07-14 Nant Holdings Ip, Llc Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections
CA3117134A1 (en) * 2019-07-08 2021-01-14 Nantkwest, Inc. Ciml nk cells and methods therefor
WO2021041886A1 (en) * 2019-08-29 2021-03-04 Nantbio, Inc. Modified n-810 and methods therefor
EP4031565A4 (en) * 2019-09-16 2023-10-25 Regents of the University of Minnesota COMPOUNDS AND METHODS FOR IMMUNOTHERAPY
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US20210188933A1 (en) * 2019-12-18 2021-06-24 Nantcell, Inc Methods of treating pancytopenia
KR20250140647A (ko) 2020-08-03 2025-09-25 난트셀, 인크. Il-15 초작용제에 대한 약물-특이적 약동학 검정
US20220227867A1 (en) * 2020-12-24 2022-07-21 Xencor, Inc. ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
CN113321736B (zh) * 2020-12-30 2024-01-09 苏州复融生物技术有限公司 一种长效化白介素15融合蛋白及其制备方法和应用
WO2022192259A1 (en) * 2021-03-09 2022-09-15 Cureimmune Therapeutics Inc. BIFUNCTIONAL HOMODIMERIC ANTI-PD-1 AND IL-15/IL-15Rα FUSION PROTEINS AND USES THEREOF
CN116655771A (zh) * 2021-05-28 2023-08-29 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
US12180492B2 (en) 2021-06-09 2024-12-31 Immunitybio, Inc. Methods and systems for producing a protein of interest in a plant
CN115806628A (zh) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 一种自分泌IL-15与anti-TIGIT结合的融合蛋白及其应用
CN116063512B (zh) * 2022-10-13 2025-11-07 深圳市百士通科技开发有限公司 多功能重组抗体及其制备方法和应用
WO2024137136A1 (en) * 2022-12-22 2024-06-27 University Of Houston System Inhibitors of il-15 and their use in treating or preventing sepsis, severe sepsis and septic shock
WO2024199355A1 (en) * 2023-03-29 2024-10-03 Starna Therapeutics Nucleic acids encoding therapeutic polypeptides and lipid nanoparticle composition comprising the nucleic acids
CN119454908A (zh) * 2023-08-08 2025-02-18 北京志道生物科技有限公司 白细胞介素复合体及其用途
WO2025085781A1 (en) * 2023-10-19 2025-04-24 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers
WO2025201438A1 (zh) * 2024-03-28 2025-10-02 上海津曼特生物科技有限公司 一种双融合蛋白及其用途
US12272439B1 (en) 2024-05-06 2025-04-08 Immunitybio, Inc. Distributed ledger for medicament administration tracking
US20260001951A1 (en) * 2024-06-28 2026-01-01 Immunitybio, Inc. Anti-SLAMF7 Antibodies And Therapeutics

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US222A (en) 1837-06-10 Truss for the retention and radical cure qe hernia
US8507A (en) 1851-11-11 petess
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
JPS551222Y2 (pl) 1975-10-07 1980-01-14
JPS551222U (pl) 1978-06-15 1980-01-07
JPS5841623Y2 (ja) 1980-06-19 1983-09-20 ミツミ電機株式会社 デイテント式スライドスイツチ装置
JPS5718916A (en) 1980-07-11 1982-01-30 Iseki Agricult Mach Shaking table sorter of automatic feeding type thresher
JPS5770185A (en) 1980-10-21 1982-04-30 Kazuo Makino Preparation of blended oil for coal liquefaction
JPS57144287A (en) 1981-03-02 1982-09-06 Toray Ind Inc Cyclopentabenzofuran derivative
JPS5841623U (ja) 1981-09-17 1983-03-18 日産デイ−ゼル工業株式会社 リアエンジンバスにおけるエンジンル−ムの冷却及び房内熱風排出装置
JPS6152156U (pl) 1984-09-12 1986-04-08
JPS6251570U (pl) 1985-09-18 1987-03-31
JPS648039U (pl) 1987-06-29 1989-01-17
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
WO1994004689A1 (en) 1992-08-14 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
PT772624E (pt) 1994-04-06 2001-03-30 Immunex Corp Interleucina-15
JPH09512165A (ja) 1994-04-06 1997-12-09 イミュネックス・コーポレーション インターロイキン１５
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DE69733610T2 (de) 1996-04-26 2006-05-11 Beth Israel Deaconess Medical Center, Inc., Boston Interleukin-15 antagonisten
DK1273304T4 (da) 1997-02-21 2009-08-31 Amgen Inc Anvendelse af interleukin-15
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
AU2001233076A1 (en) 2000-02-01 2001-08-14 Michael A. O'donnell Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
EP2322228B1 (en) 2000-06-05 2018-01-10 Altor BioScience Corporation T cell receptor fusion proteins and conjugates and methods of use thereof
ATE427318T1 (de) 2000-09-14 2009-04-15 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
JP2003026599A (ja) 2001-06-11 2003-01-29 Univ Nagoya Ｉｌ−１５遺伝子を応用したワクチンアジュバント
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
US20040156826A1 (en) 2002-09-27 2004-08-12 Fernando Dangond Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
UA91325C2 (ru) * 2002-12-26 2010-07-26 Маунтин Вью Фармасьютикалз, Инк. Полимерные конъюгаты цитокинов, хемокинов, факторов роста, полипептидных гормонов и их антагонистов с сохраненной активностью рецепторного связывания
ZA200506724B (en) 2003-02-26 2007-03-28 Genmab As Human antibodies specific for interleukin 15 (IL-15)
DE10324708A1 (de) 2003-05-30 2004-12-16 Ltn Servotechnik Gmbh Schleifringelement und Verfahren zu dessen Herstellung
CN1233822C (zh) 2003-09-05 2005-12-28 中国科学技术大学 白细胞介素－15基因修饰的自然杀伤细胞株及其制备方法
US8772451B2 (en) 2003-11-10 2014-07-08 Altor Bioscience Corporation Soluble TCR molecules and methods of use
EP1718670B1 (en) 2004-02-27 2011-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity
EP1586585A1 (de) 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
CN100334112C (zh) 2004-10-15 2007-08-29 上海海欣生物技术有限公司 人白细胞介素15与Fc融合蛋白
WO2006065495A2 (en) 2004-11-24 2006-06-22 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
MX2007006832A (es) 2004-12-13 2007-08-07 Cytos Biotechnology Ag Arreglos de antigeno interleucina 15 y usos de los mismos.
AU2011203119C1 (en) * 2005-05-09 2018-06-14 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
DK1873166T3 (da) 2006-06-30 2010-12-20 Conaris Res Inst Ag Forbedrede sgp 130Fc-dimerer
US7965180B2 (en) 2006-09-28 2011-06-21 Semiconductor Energy Laboratory Co., Ltd. Wireless sensor device
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
DK2160401T3 (da) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
AU2013273643C1 (en) 2007-05-11 2016-08-11 Altor Bioscience Corporation Fusion molecules and il-15 variants
JP2010530895A (ja) 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
NZ582330A (en) 2007-06-27 2012-05-25 Marinepolymer Tech Inc COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF
WO2009117117A1 (en) 2008-03-19 2009-09-24 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use there of
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
EP2670847B1 (en) * 2011-02-03 2016-10-05 XOMA Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
NZ630790A (en) * 2012-10-24 2016-11-25 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
SI3094351T1 (sl) 2014-01-15 2022-05-31 Kadmon Corporation, Llc Imunomodulatorna sredstva
CA3151221C (en) 2014-06-30 2026-01-13 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
CN104672325A (zh) 2015-03-11 2015-06-03 福建农林大学 一种用新鲜螺旋藻制备藻蓝蛋白的方法
KR20180125435A (ko) 2015-09-25 2018-11-23 알토 바이오사이언스 코포레이션 이식편 대 종양 활성을 현저하게 향상시키는 인터루킨-15 수퍼아고니스트
AU2017271593B2 (en) 2016-05-27 2021-04-22 Altor Bioscience Corporation Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
CN118562016A (zh) 2016-10-21 2024-08-30 艾尔特生物科技公司 基于多聚体il-15的分子
TW202003011A (zh) 2018-03-26 2020-01-16 美商艾爾特生物科技責任有限公司 抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子

Also Published As

Publication number Publication date
US20230233649A1 (en) 2023-07-27
AU2015284248B2 (en) 2020-04-16
US20200016239A1 (en) 2020-01-16
US20250262278A1 (en) 2025-08-21
EP3160498A2 (en) 2017-05-03
US20150374790A1 (en) 2015-12-31
US11925676B2 (en) 2024-03-12
US12318432B2 (en) 2025-06-03
EP3160498A4 (en) 2017-12-06
JP2021176880A (ja) 2021-11-11
WO2016004060A2 (en) 2016-01-07
AU2020204408A1 (en) 2020-07-23
KR20210092338A (ko) 2021-07-23
KR102398246B1 (ko) 2022-05-17
EP3160498B1 (en) 2021-10-06
US20240131115A1 (en) 2024-04-25
MX2017000116A (es) 2017-05-30
CN112494646A (zh) 2021-03-16
US20240299498A1 (en) 2024-09-12
CN106659775B (zh) 2021-08-06
US20220305087A1 (en) 2022-09-29
KR102503476B1 (ko) 2023-02-24
JP2023081999A (ja) 2023-06-13
JP6842926B2 (ja) 2021-03-17
EP3912637A1 (en) 2021-11-24
AU2024204957A1 (en) 2024-08-08
US11471511B2 (en) 2022-10-18
JP2025000709A (ja) 2025-01-07
AU2020204408B2 (en) 2022-03-24
CN113384686B (zh) 2024-11-01
EP3673915A1 (en) 2020-07-01
AU2015284248A1 (en) 2017-01-12
JP2017521410A (ja) 2017-08-03
KR20170047221A (ko) 2017-05-04
KR20230028807A (ko) 2023-03-02
US12186372B2 (en) 2025-01-07
US20210030844A1 (en) 2021-02-04
CA2953816C (en) 2022-03-15
KR102762243B1 (ko) 2025-02-05
US20230190877A1 (en) 2023-06-22
US20230241174A1 (en) 2023-08-03
JP2020128390A (ja) 2020-08-27
AU2022201758B2 (en) 2024-07-18
MX387159B (es) 2025-03-18
KR20250020700A (ko) 2025-02-11
CA3151221A1 (en) 2016-01-07
ES2899890T3 (es) 2022-03-15
US12097244B2 (en) 2024-09-24
US11890323B2 (en) 2024-02-06
US20260061033A1 (en) 2026-03-05
US12268732B2 (en) 2025-04-08
US12268731B2 (en) 2025-04-08
US20230241175A1 (en) 2023-08-03
JP7561905B2 (ja) 2024-10-04
US20240261373A1 (en) 2024-08-08
US9925247B2 (en) 2018-03-27
CN113384686A (zh) 2021-09-14
AU2022201758A1 (en) 2022-04-07
US20250262277A1 (en) 2025-08-21
US20240307494A1 (en) 2024-09-19
US10537615B2 (en) 2020-01-21
US11992516B2 (en) 2024-05-28
WO2016004060A3 (en) 2016-03-17
CA2953816A1 (en) 2016-01-07
US11173191B2 (en) 2021-11-16
CN106659775A (zh) 2017-05-10
US20190022187A1 (en) 2019-01-24
CA3151221C (en) 2026-01-13
US11679144B2 (en) 2023-06-20
US20240307495A1 (en) 2024-09-19
US20240252591A1 (en) 2024-08-01
WO2016004060A9 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
PL3160498T3 (pl) Cząsteczki na bazie IL-15 i sposoby ich zastosowania
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
IL251970B (en) Anti-cd79b antibodies and methods of use
IL282048A (en) Oxysterols and methods of use thereof
IL254039A0 (en) Anti-pvrig antibodies and methods of use
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
PL3215532T3 (pl) Przeciwciała anty-TIM3 i sposoby ich zastosowania
IL251972B (en) Analyzing and utilizing landscapes
ME03558B (me) Molekuli anti-lag-3 antiтela i njihove upotrebe
IL249092A0 (en) Anti-gitr antibodies and methods of use thereof
HRP20251095T1 (hr) Neoantigeni i metode njihove uporabe
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
HUE052373T2 (hu) Szubsztituált krománok és alkalmazási eljárások
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
DK3169704T3 (da) Molekyler med specificitet for cd45 og cd79
IL251988A0 (en) Glycan-interacting compounds and methods of use
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
BR112017004648A2 (pt) simuladores mir-29 e os usos deste
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
MA41997A (fr) Combinaisons de cannabinoïdes et de n-acyléthanolamines
HUE059701T2 (hu) Antitestek és felhasználási módszerek
DK3137873T3 (da) Viscometer and methods of use thereof